Drugs / Ubamatamab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07637851 | Aug 2026 → Sep 2028 expected | ovarian cancer | ARCAGY/ GINECO GROUP | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04590326 | Dec 2020 → Nov 2028 expected | endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03564340 | May 2018 → May 2027 expected | endometrial cancer, fallopian tube cancer, malignant ovarian serous tumor, primary peritoneal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07154290 | Mar 2026 → Jun 2030 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06787612 | May 2025 → Jun 2028 expected | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06444880 | Oct 2024 → Jul 2028 expected | epithelioid sarcoma, kidney medullary carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT07502716 Background | — | epithelioid sarcoma, kidney medullary carcinoma | Regeneron Pharmaceuticals | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-10-06 | Regeneron Pharmaceuticals | Results Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 regeneron.com ↗
Circulating tumor DNA (ctDNA), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) associate with survival outcomes in patients with platinum-resistant ovarian cancer treated with ubamatamab |
| 2026-10-01 | Regeneron Pharmaceuticals | Results Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first results for the investigational ubamatamab in patients with low-grade serous ovarian cancer (LGSOC). |
| 2022-09-10 | Regeneron Pharmaceuticals | Results Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early data for two novel and investigational bispecific antibodies – ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer (NSCLC). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-06 | Regeneron Pharmaceuticals | Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 regeneron.com ↗ |
| 2026-10-01 | Regeneron Pharmaceuticals | Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) regeneron.com ↗ |
| 2022-09-10 | Regeneron Pharmaceuticals | Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors regeneron.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ubamatamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07154290 ↗ |
| Known as | REGN-4018 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594595 ↗ |
| Action | Deplete | “promotes T-cell-mediated cytotoxicity of MUC16-expressing cells” PMID 39652449 ↗ Dec 2024 |
| Modality | Monoclonal antibody | — CHEMBL4594595 ↗ |
| Route | Intravenous | “Intravenous administration of ubamatamab” PMID 39652449 ↗ Dec 2024 |
| Target | MUC16 | “a novel bispecific T-cell engager (MUC16xCD3)” PMID 40749151 ↗ Aug 2025 |